Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939952 · ClinicalTrials.gov registry record · Phase 4
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
A Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis, sponsored by Albany College of Pharmacy and Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00939952: Completed Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis, sponsored by Albany College of Pharmacy and Health Sciences.
NCT00939952 is a Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis that has completed, run by Albany College of Pharmacy and Health Sciences. The registered enrollment target is 7 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939952, a Phase 4 study of End Stage Renal Disease and Continuous Ambulatory Peritoneal Dialysis, has completed, sponsored by Albany College of Pharmacy and Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).
Primary Outcome
Population PK
Conditions Studied
Interventions
- DRUG ertapenem
Study Locations (1)
New York
- Hortense and Louis Rubin Dialysis Center - Clifton Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
What the finished NCT00939952 record still lists
NCT00939952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which ertapenem is the first listed.
NCT00939952 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00939952 about?
NCT00939952 is a clinical study titled "Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis". The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).
What is the current status of trial NCT00939952?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2009-06. Estimated completion is 2010-05.
What conditions does trial NCT00939952 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis.
What interventions are being tested in trial NCT00939952?
The interventions under investigation include: ertapenem (DRUG).
Who is sponsoring clinical trial NCT00939952?
This trial is sponsored by Albany College of Pharmacy and Health Sciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00939952 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00939952's enrollment target sits among peer trials
7 84th of 86 higher than 2 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia